Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Prolyl-Hydroxylase Inhibitors to Activate Hypoxia-Inducible Factor (HIF) as a Novel Therapeutic Approach in CKD

Journal of Pharmacological Sciences - Japan
doi 10.1254/jphs.08r09fm
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Japanese Pharmacological Society

Related search

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD

American Journal of Kidney Diseases
Nephrology
2017English

Drug Discovery for Overcoming Chronic Kidney Disease (CKD): The Endothelin ETB Receptor / Nitric Oxide System Functions as a Protective Factor in CKD

Journal of Pharmacological Sciences
Molecular MedicinePharmacology
2009English

Retarding Chronic Kidney Disease (CKD) Progression: A Practical Nutritional Approach for Non-Dialysis CKD

Nephrology @ Point of Care
2016English

ExActa HIF Prolyl Hydroxylase Inhibitors – The New Lifestyle Drug?

Acta Physiologica
Physiology
2019English

Author Correction: Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitors Induce Autophagy and Have a Protective Effect in an In-Vitro Ischaemia Model

Scientific Reports
Multidisciplinary
2020English

Mucosal Protection by Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibition

Gastroenterology
HepatologyGastroenterology
2008English

The Unfolded Protein Response: A Novel Insight Into Chronic Kidney Disease (CKD)

Nephrology – Open Journal
2017English

Roles of Coagulation Pathway and Factor Xa in Chronic Kidney Disease (CKD)

Yakugaku Zasshi
PharmacologyPharmaceutical Science
2012English

Rationale and Design of a Multicenter Chronic Kidney Disease (CKD) and At-Risk for CKD Electronic Health Records-Based Registry: CURE-CKD

BMC Nephrology
Nephrology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy